<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the results of unrelated cord blood transplantation (CBT) for 13 adult patients with advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The median age was 40 years, the median weight was 51 kg, and the median number of infused nucleated cells was 2.43 x 107/kg </plain></SENT>
<SENT sid="2" pm="."><plain>Twelve patients had myeloid reconstitution, and the median time to more than 0.5 x 109/L (5 x 108/L) absolute neutrophil count was 22.5 days </plain></SENT>
<SENT sid="3" pm="."><plain>A self-sustained platelet count more than 50 x 109/L was achieved in 11 patients at a median time of 49 days </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> (GVHD) occurred in 9 of 12 evaluable patients and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD in 8 of 11 evaluable patients </plain></SENT>
<SENT sid="5" pm="."><plain>Ten patients are alive and free of disease at between 171 and 1558 days after transplantation </plain></SENT>
<SENT sid="6" pm="."><plain>The probability of disease-free survival at 2 years was 76.2% </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest that adult advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT </plain></SENT>
</text></document>